ID

15393

Description

Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02150317

Link

https://clinicaltrials.gov/show/NCT02150317

Keywords

  1. 5/29/16 5/29/16 -
Uploaded on

May 29, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Advanced Hepatocellular Carcinoma NCT02150317

Eligibility Advanced Hepatocellular Carcinoma NCT02150317

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
male or female patients > 18 years and <=70 years of age.
Description

age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
at least 2 radiologic imaging showing characteristic features of hepatocellular carcinoma or cytologic/histologic evidence.
Description

hepatocellular carcinoma

Data type

boolean

Alias
UMLS CUI [1]
C2239176
tumor in liver and radiologically definable vascular invasion or extrahepatic metastasis.
Description

vascular invasion or extrahepatic metastasis

Data type

boolean

Alias
UMLS CUI [1]
C0521157
UMLS CUI [2]
C0474915
criteria of liver function: child a-b level, serum bilirubin ≤ 1.5 times the upper limit of normal value,alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper limit of normal value.
Description

child a-b level, serum bilirubin

Data type

boolean

Alias
UMLS CUI [1]
C4050412
UMLS CUI [2]
C0428441
no dysfunction in major organs; blood routine, kidney function, cardiac function and lung function are basically normal.
Description

major organs

Data type

boolean

Alias
UMLS CUI [1]
C0026766
hb ≥90g/l,white blood cell count ≥3.000 cells/mm³,platelets ≥80.000 cells/mm³
Description

white blood cell count

Data type

boolean

Alias
UMLS CUI [1]
C0023508
patients who can understand this trial and have signed informed consent
Description

informed consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with apparent cardiac, pulmonary, cerebral and renal dysfunction, which may affect the treatment of liver cancer.
Description

Study Subject Participation Status

Data type

boolean

Alias
UMLS CUI [1]
C0525058
UMLS CUI [2]
C0009488
patients with a medical history of other malignant tumors
Description

Malignant Neoplasms

Data type

boolean

Alias
UMLS CUI [1]
C0006826
subjects participating in other clinical trials
Description

subjects participating in other clinical trials

Data type

boolean

Alias
UMLS CUI [1]
C2348568
liver function:child c
Description

Child-Pugh Class C

Data type

boolean

Alias
UMLS CUI [1]
C3831115
no pathological evidence of hepatocellular carcinoma.
Description

no pathological evidence of hepatocellular carcinoma.

Data type

boolean

Alias
UMLS CUI [1]
C0205469

Similar models

Eligibility Advanced Hepatocellular Carcinoma NCT02150317

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
age
Item
male or female patients > 18 years and <=70 years of age.
boolean
C0001779 (UMLS CUI [1])
hepatocellular carcinoma
Item
at least 2 radiologic imaging showing characteristic features of hepatocellular carcinoma or cytologic/histologic evidence.
boolean
C2239176 (UMLS CUI [1])
vascular invasion or extrahepatic metastasis
Item
tumor in liver and radiologically definable vascular invasion or extrahepatic metastasis.
boolean
C0521157 (UMLS CUI [1])
C0474915 (UMLS CUI [2])
child a-b level, serum bilirubin
Item
criteria of liver function: child a-b level, serum bilirubin ≤ 1.5 times the upper limit of normal value,alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper limit of normal value.
boolean
C4050412 (UMLS CUI [1])
C0428441 (UMLS CUI [2])
major organs
Item
no dysfunction in major organs; blood routine, kidney function, cardiac function and lung function are basically normal.
boolean
C0026766 (UMLS CUI [1])
white blood cell count
Item
hb ≥90g/l,white blood cell count ≥3.000 cells/mm³,platelets ≥80.000 cells/mm³
boolean
C0023508 (UMLS CUI [1])
informed consent
Item
patients who can understand this trial and have signed informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Study Subject Participation Status
Item
patients with apparent cardiac, pulmonary, cerebral and renal dysfunction, which may affect the treatment of liver cancer.
boolean
C0525058 (UMLS CUI [1])
C0009488 (UMLS CUI [2])
Malignant Neoplasms
Item
patients with a medical history of other malignant tumors
boolean
C0006826 (UMLS CUI [1])
subjects participating in other clinical trials
Item
subjects participating in other clinical trials
boolean
C2348568 (UMLS CUI [1])
Child-Pugh Class C
Item
liver function:child c
boolean
C3831115 (UMLS CUI [1])
no pathological evidence of hepatocellular carcinoma.
Item
no pathological evidence of hepatocellular carcinoma.
boolean
C0205469 (UMLS CUI [1])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial